Schizophrenia and bipolar disorder are mental disorders that pose a real problem to the public health care system. Early diagnosis and treatment is instrumental in a relatively good management and control of these two diseases. Second-generation antipsychotics increase the likelihood of selecting the right, optimal medicine, which enables effective treatment at reduced strength and frequency of adverse reactions. We conducted a post-authorisation study in which 163 patients with schizophrenia and bipolar mania received olanzapine in the form of regular and orodispersible tablets (Zolrix®/Zolrix® orodispersible tablets, Krka, d.d., Novo mesto). Treatment with an average dose of 12.7 mg of olanzapine reduced symptom expression in 79% of patients. Due to improvement in symptoms 41% of patients became only margi nally ill or even symptom-free. Olanzapine was very well tolerated by patients. Only in 25.2% of patients
medicine-related adverse reactions were noted during monitoring, while at the end of monitoring the number fell to 17.8%. The post-authorisation study showed that the most frequent adverse reaction was weight gain, which was present in only 11% of patients treated with olanzapine.